Clinical Trial Update: Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluated the combination of trastuzumab (Herceptin) and tanespimycin in patients with solid tumors and HER2-positive metastatic bre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumors

Drugs mentioned

• HERCEPTIN (trastuzumab)
• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Solid Tumors, Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED